MAPK8 and cutaneous squamous cell carcinoma: In contrast, it was recently shown that ZAK inhibition by Sorafinib causes cutaneous squamous cell carcinoma due to suppression of JNK activity (Vin et al., 2014), which might explain why over-expression of exogenous ZAK lead to reduced viability.